Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...

The CANMILK project has reached a major milestone: three years of collaborative research dedicated to reducing methane emissions in agriculture through innovative plasma-based technology. This press ...

The U.S. Food and Drug Administration said on Friday it is investigating the death of a child who developed harmful ...

The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the ...

FDA reports rare neutralizing antibodies, including a pediatric death, in patients treated with Takeda's Adzynma for ...

Takeda Pharmaceutical (TAK) stock is in focus as the company's blood disease drug Adzynma is linked to a patient death, ...

ADMA Biologics has demonstrated impressive operational performance in its latest quarterly report, but the company's true ...

Lower baseline low-density lipoprotein cholesterol levels are linked to a higher risk for incident type 2 diabetes, largely ...

Our data shows that as many as 20% of breast cancer survivors on aromatase inhibitors will stop taking their medication ...

Takenobu Y, Kikuchi T, Ishikawa D, et al. Rozanolixizumab as rescue therapy in triple seronegative refractory generalized ...

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

Australian biotech firm CSL said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, ...